Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.34 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22386545 | 0.89 | EPHX1 (0.33) | EPHX1HDAC4HDAC1HDAC3HDAC7 | |
| SCHEMBL26616752 | 0.87 | PAOX (0.36) | HDAC4HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL25919987 | 0.86 | MAPT (0.40) | EPHX1EPHX2FOLH1 | |
| SCHEMBL20029380 | 0.83 | FOLH1 (0.35) | EPHX1ASAH2PAOXGRIA1FOLH1 | |
| SCHEMBL25919981 | 0.82 | EPHX1 (0.41) | EPHX1HDAC4HDAC1HDAC3HDAC7 | |
| SCHEMBL22386546 | 0.80 | MAPT (0.39) | EPHX1FOLH1 | |
| SCHEMBL26045235 | 0.79 | TSHR (0.34) | EPHX1HDAC4HDAC1GRIA1 | |
| SCHEMBL22386550 | 0.78 | EPHX1 (0.41) | EPHX1HDAC4HDAC1HDAC3HDAC7 | |
| SCHEMBL807923 | 0.78 | EPHX1 (0.41) | EPHX1HDAC4HDAC1HDAC3HDAC7 | |
| SCHEMBL22386555 | 0.77 | PAOX (0.31) | PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248836-A1 | Dosage Regimen for a Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-08-10 | — | — | US | disclosed |
| US-20230218722-A1 | PTH Compounds with Low Peak-To-Trough Ratios | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248836-A1 | Dosage Regimen for a Controlled-Release PTH Compound | PTH1R, CALCA, CALCR | EPHX1 2663/4885HDAC4 859/4885HDAC1 2710/4885 |
| US-20230218722-A1 | PTH Compounds with Low Peak-To-Trough Ratios | PTH1R, PTMS, FGF23 | EPHX1 1814/4885HDAC4 2359/4885HDAC1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.